We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
GlaxoSmithKline had several years to prepare for the U.S. generic assault on its respiratory blockbuster Advair, offering discounts and rolling out new therapies to stay in the game.